This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-25. (canceled)

26. (currently amended) A method for delivering a pharmaceutical polypeptide agent through a body surface~~,~~ comprising:

(a) ~~providing~~ preparing a synthetic analog of a parent human growth hormone releasing hormone (SEQ ID NO:8) ~~having~~ by replacing at least one glutamine residue at position 16, 30, 31, or 36 of the parent human growth hormone releasing hormone ~~replaced~~ with a histidine residue; and

(b) delivering the synthetic analog through the body surface by electrotransport.

27-28. (canceled)

29. (currently amended) The method of claim 26 wherein the synthetic analog is prepared by replacing the glutamine residues at positions 31 and 36 of the parent human growth hormone releasing hormone ~~analog are replaced~~ with histidine residues.

30. (currently amended) The method of claim 26 wherein the synthetic analog has increased ~~hydrophobicity~~ hydrophilicity and electrophoretic mobility ~~at the pH of electrotransport of the analog are increased~~ relative to that of the parent ~~polyptptide~~ human growth hormone releasing hormone.

31. (currently amended) The method of claim 26 wherein the synthetic analog exhibits at least about the same type and amount of biological activity as the parent ~~polyptptide~~ human growth hormone releasing hormone.

32. (currently amended) The method of claim 26 wherein the overall charge of the synthetic analog is positive at a pH in the range of about 5 to 6 but substantially isoelectric at pH 7.4.

33. (currently amended) The method of claim 32 wherein the synthetic analog has a greater positive charge at a pH in the range of about 5 to 6 than the parent ~~polyptptide~~ human growth hormone releasing hormone.

34. (currently amended) The method of claim 26 wherein the synthetic analog is provided in the form of an anionic donor reservoir formulation for delivering the synthetic analog through the body surface by electrotranpsort, the formulation having a pH in the range of about 3.5 to about ~~7.4~~ 8.

35. (currently amended) The method of claim 34 wherein the formulation used for delivering the synthetic analog by electrotransport has a pH in the range of about 5 to about ~~7.4~~ 6.

36. (currently amended) A method for delivering a pharmaceutical polypeptide agent through a body surface~~,~~ comprising:

(a) ~~providing~~ preparing a synthetic analog of a parent human growth hormone releasing hormone (SEQ ID NO:8) ~~having~~ by replacing at least two glutamine residues at positions 16, 24, 30, 31, or 36 of the parent human growth hormone releasing hormone ~~replaced~~ with histidine residues; and

(b) delivering the synthetic analog through the body surface by electrotransport.

37. (currently amended) The method of claim 36 wherein the synthetic analog is prepared by replacing the glutamine residues at positions 16, 24, 30, and 31 of the parent human growth hormone releasing hormone ~~analog are replaced~~ with histidine residues.

38. (currently amended) The method of claim 36 wherein the synthetic analog has increased ~~hydrophobicity~~ hydrophilicity and electrophoretic mobility ~~at the pH of electrotransport of the analog are increased~~ relative to that of the parent ~~polyptptide~~ human growth hormone releasing hormone.

39. (currently amended) The method of claim 36 wherein the synthetic analog exhibits at least about the same type and amount of biological activity as the parent ~~polypeptide~~ human growth hormone releasing hormone.

40. (currently amended) The method of claim 36 wherein the overall charge of the synthetic analog is positive at a pH in the range of about 5 to 6 but substantially isoelectric at pH 7.4.

41. (currently amended) The method of claim 40 wherein the synthetic analog has a greater positive charge at a pH in the range of about 5 to 6 than the parent ~~polypeptide~~ human growth hormone releasing hormone.

42. (currently amended) The method of claim 36 wherein the synthetic analog is provided in the form of an anionic donor reservoir formulation for delivering the synthetic analog through the body surface by electrotranpsort, the formulation having a pH in the range of about 3.5 to about ~~7.4~~ 8.

43. (currently amended) The method of claim 42 wherein the formulation used for delivering the synthetic analog by electrotransport has a pH in the range of about 5 to about ~~7.4~~ 6.